Biomedical Bonding AB secures Eurostars funding for its light-cured implants for the treatment of bone fractures
Biomedical Bonding AB, a Swedish MedTech company with focus on patient-personalized implants for the treatment of bone fractures, together with its partners Ivoclar Vivadent Manufacturing GmbH in Austria and RISE Research Institutes of Sweden have secured funding from the Eurostars program to accelerate the development of their new universal composite plating fixators.
Biomedical Bonding (BMB) has together with RISE Research Institutes of Sweden and Ivoclar been granted funding from the Eurostars program.
Out of 432 project applications, the consortium’s proposal scored high and will receive funding from Vinnova (Sweden) and FFG (Austria). In the project, BMB will take the next step with its Bonevolent™ technology by partnering with experts in medical device testing and a global leader in light-cured dental materials.
“We are pleased and delighted that the Eurostars program has funded this exciting project. Our mission is to become the first MedTech company to provide bone-like composite implants that adapts to the fractures instead of fixating the fractures with predesigned metal plates. We are continuously seeking collaborations with key industrial partners and the alliance with RISE and Ivoclar will accelerate our activities to provide first mover pioneering implants for clinical trials in parallel with the development of the necessary instruments”, says Michael Malkoch, CEO and Founder of BMB.
The two-year Eurostars project have a total budget of €1.35M and will start in June 2022, with BMB as leading part and managed by the company’s CTO Viktor Granskog.
This project is co-funded by EUREKA member countries and the European Union Horizon Europe Framework Program.